Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Finished Goods: 2020-2025

Historic Finished Goods for Fortress Biotech (FBIO) over the last 4 years, with Mar 2025 value amounting to $10.0 million.

  • Fortress Biotech's Finished Goods rose 70.95% to $10.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $10.0 million, marking a year-over-year increase of 70.95%. This contributed to the annual value of $11.4 million for FY2024, which is 128.21% up from last year.
  • According to the latest figures from Q1 2025, Fortress Biotech's Finished Goods is $10.0 million, which was down 11.91% from $11.4 million recorded in Q4 2024.
  • Over the past 5 years, Fortress Biotech's Finished Goods peaked at $11.4 million during Q4 2024, and registered a low of $4.3 million during Q4 2021.
  • In the last 3 years, Fortress Biotech's Finished Goods had a median value of $6.9 million in 2023 and averaged $7.6 million.
  • In the last 5 years, Fortress Biotech's Finished Goods skyrocketed by 205.56% in 2021 and then crashed by 35.56% in 2023.
  • Fortress Biotech's Finished Goods (Quarterly) stood at $4.3 million in 2021, then skyrocketed by 80.40% to $7.7 million in 2022, then crashed by 35.56% to $5.0 million in 2023, then soared by 128.21% to $11.4 million in 2024, then skyrocketed by 70.95% to $10.0 million in 2025.
  • Its Finished Goods was $10.0 million in Q1 2025, compared to $11.4 million in Q4 2024 and $8.7 million in Q3 2024.